Lexicon Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Lexicon Pharmaceuticals

03/05/2024 20:53

* Lexicon Pharmaceuticals Inc  LXRX.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended in
March, lower than the same quarter last year, when the company
reported EPS of -17 cents.  The mean expectation of
five analysts for the quarter was for a loss of 20 cents per
share. Wall Street expected results to range from -20 cents
to -19 cents per share.
    * Revenue rose 4,608.3% to $1.13 million from a year ago;
analysts
expected $1.40 million. 
    * Lexicon Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 20 cents​.
    * The company reported a quarterly loss of $48.4 million.
    * Lexicon Pharmaceuticals Inc shares had fallen by 29.2%
this
quarter and gained 11.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 8.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Lexicon
Pharmaceuticals Inc is $4.50 

This summary was machine generated from LSEG data May 3 at 07:52
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.20          -0.20          Met
 Dec. 31 2023      -0.22          -0.20          Beat
 Sep. 30 2023      -0.21          -0.21          Met
 Jun. 30 2023      -0.17          -0.22          Missed